SR9009 Solution, 600mg (20mg/mL)
Clinical research has shown that SR9009 may have the ability to;
✓ Increase endurance and reduce recovery time.
✓ Burn fat by increasing glucose uptake in skeletal muscle tissue.
✓ Increase resting metabolic rate.
✓ Reduce inflammation and prevent oxidative damage to blood vessels.
Note: Products are for laboratory research use only. Not for human use. Reference Materials are not therapeutics and we do not sell to patients.
|AUD $149.00||AUD $146.50||AUD $144.00||AUD $139.00||AUD $129.00|
|Molar Mass||437.94 g/mol|
|IUPAC Name||ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate|
|Synonyms||SHRED, Sr9009, SR-9009, SR 9009, Stenabolic|
|Country of Origin||USA|
|Terms of sale||This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Information presented is based upon evidence found in clinical studies. Research products sold on this site are not bound by the ‘Therapeutic Goods Act of 1989’. Please familiarise yourself with our Terms & Conditions prior to ordering.|
Although Stenabolic SR9009 is usually grouped into the category of SARMS, it is actually a PPAR modulator. It works by activating AMP-activated protein kinase and stimulating glucose uptake in skeletal muscle tissue. Stenabolic (SR9009) has been studied for its ability to reverse metabolic disorders and was considered as a treatment for obesity. It was shown to be very successful in this regard.
When used in clinical trials, Stenabolic (SR9009) was shown to increase the subjects resting metabolic rate, while positively influencing lipid and glucose metabolism in the liver.
SR 9009 was also shown to impact the reaction of macrophages. Macrophages are cells that eliminate dead and dying cells from the body during inflammation
Studies of Stenabolic (SR9009) suggest dosages can be approximately 10mg, twice per day – due to a shorter half life.
Studies and additional info: